JPS60256460A - フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 - Google Patents
フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物Info
- Publication number
- JPS60256460A JPS60256460A JP59109693A JP10969384A JPS60256460A JP S60256460 A JPS60256460 A JP S60256460A JP 59109693 A JP59109693 A JP 59109693A JP 10969384 A JP10969384 A JP 10969384A JP S60256460 A JPS60256460 A JP S60256460A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bone
- calcium phosphate
- filling
- phosphate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000988 bone and bone Anatomy 0.000 title claims description 62
- 239000000203 mixture Substances 0.000 title claims description 44
- 230000007547 defect Effects 0.000 title claims description 38
- 238000011049 filling Methods 0.000 title claims description 36
- 239000001506 calcium phosphate Substances 0.000 title claims description 32
- -1 calcium phosphate compound Chemical class 0.000 title claims description 27
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims description 26
- 235000011010 calcium phosphates Nutrition 0.000 title claims description 26
- 102000009123 Fibrin Human genes 0.000 title claims description 23
- 108010073385 Fibrin Proteins 0.000 title claims description 23
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims description 23
- 229950003499 fibrin Drugs 0.000 title claims description 23
- 239000000843 powder Substances 0.000 description 29
- 108010049003 Fibrinogen Proteins 0.000 description 26
- 102000008946 Fibrinogen Human genes 0.000 description 26
- 229940012952 fibrinogen Drugs 0.000 description 26
- 239000008187 granular material Substances 0.000 description 15
- 108090000190 Thrombin Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 229960004072 thrombin Drugs 0.000 description 12
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 11
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 11
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 description 5
- 229940078499 tricalcium phosphate Drugs 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000005422 Foreign-Body reaction Diseases 0.000 description 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 239000002956 ash Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052587 fluorapatite Inorganic materials 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 239000012035 limiting reagent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 description 1
- 101710082399 Alpha-protein kinase 3 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000001621 ilium bone Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59109693A JPS60256460A (ja) | 1984-05-31 | 1984-05-31 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
| EP85106694A EP0166263A1 (en) | 1984-05-31 | 1985-05-30 | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59109693A JPS60256460A (ja) | 1984-05-31 | 1984-05-31 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60256460A true JPS60256460A (ja) | 1985-12-18 |
| JPH047227B2 JPH047227B2 (enrdf_load_stackoverflow) | 1992-02-10 |
Family
ID=14516800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59109693A Granted JPS60256460A (ja) | 1984-05-31 | 1984-05-31 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60256460A (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777001B1 (en) | 1996-11-25 | 2004-08-17 | Kabushiki Kaisya Advance | Method of production of ceramics |
| JP2009538285A (ja) * | 2006-05-26 | 2009-11-05 | バクスター・インターナショナル・インコーポレイテッド | 骨造成のための注射用フィブリン組成物 |
| JP2011525380A (ja) * | 2008-06-23 | 2011-09-22 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | リン酸カルシウムを含有する生体材料 |
| US9248215B2 (en) | 2006-05-26 | 2016-02-02 | Baxter International Inc. | Injectable bone void filler |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836545A (ja) * | 1981-06-25 | 1983-03-03 | セラフアルム ジ−エムビ−エイチ アンド カンパニ− ケイジイ | フイブリノ−ゲンを含有する乾燥製剤およびその製造方法 |
-
1984
- 1984-05-31 JP JP59109693A patent/JPS60256460A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836545A (ja) * | 1981-06-25 | 1983-03-03 | セラフアルム ジ−エムビ−エイチ アンド カンパニ− ケイジイ | フイブリノ−ゲンを含有する乾燥製剤およびその製造方法 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777001B1 (en) | 1996-11-25 | 2004-08-17 | Kabushiki Kaisya Advance | Method of production of ceramics |
| JP2009538285A (ja) * | 2006-05-26 | 2009-11-05 | バクスター・インターナショナル・インコーポレイテッド | 骨造成のための注射用フィブリン組成物 |
| JP2013017842A (ja) * | 2006-05-26 | 2013-01-31 | Baxter Internatl Inc | 骨造成のための注射用フィブリン組成物 |
| US9248215B2 (en) | 2006-05-26 | 2016-02-02 | Baxter International Inc. | Injectable bone void filler |
| US9421302B2 (en) | 2006-05-26 | 2016-08-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
| US9724449B2 (en) | 2006-05-26 | 2017-08-08 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
| JP2011525380A (ja) * | 2008-06-23 | 2011-09-22 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | リン酸カルシウムを含有する生体材料 |
| JP2014195712A (ja) * | 2008-06-23 | 2014-10-16 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | リン酸カルシウムを含有する生体材料 |
| US9233124B2 (en) | 2008-06-23 | 2016-01-12 | Centre National De La Recherche Scientifique | Biomaterials containing calcium phosphate |
| US9421227B2 (en) | 2008-06-23 | 2016-08-23 | Centre National De La Recherche Scientifique | Biomaterials containing calcium phosphate |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH047227B2 (enrdf_load_stackoverflow) | 1992-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Costantino et al. | Hydroxyapatite cement: I. Basic chemistry and histologic properties | |
| JP3035316B2 (ja) | 被覆された生物材料および該生物材料の製造方法 | |
| US5047031A (en) | In situ calcium phosphate minerals method | |
| JP5792633B2 (ja) | モネタイトと他の生物活性カルシウムの複合物及びシリコン化合物に基づく骨再生材料 | |
| Guillemin et al. | The use of coral as a bone graft substitute | |
| Yaylaoǧlu et al. | Development of a calcium phosphate–gelatin composite as a bone substitute and its use in drug release | |
| US6201039B1 (en) | Bone substitute composition comprising hydroxyapatite and a method of production therefor | |
| EP0347028B1 (en) | Calcium phosphate mineral compositions and methods for preparing same | |
| US5129905A (en) | Methods for in situ prepared calcium phosphate minerals | |
| US6005162A (en) | Methods of repairing bone | |
| US6002065A (en) | Kits for preparing calcium phosphate minerals | |
| CN100536936C (zh) | 一种无机植骨材料、其制备方法及用途 | |
| JPH0156777B2 (enrdf_load_stackoverflow) | ||
| JPH01236058A (ja) | 骨修復組成物及び方法 | |
| Fernandes et al. | Calcium sulfate as a scaffold for bone tissue engineering: a descriptive review | |
| JPS6017118A (ja) | リン酸カルシウム質フアイバ− | |
| JPH0233388B2 (enrdf_load_stackoverflow) | ||
| Arahira et al. | Characterization and in vitro evaluation of biphasic α-tricalcium phosphate/β-tricalcium phosphate cement | |
| RU2494721C1 (ru) | Биосовместимый костнозамещающий материал и способ получения его | |
| KR101777427B1 (ko) | 칼슘 포스페이트를 함유하는 생체재료 | |
| JPS60256460A (ja) | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 | |
| JPS60256461A (ja) | 骨欠損部及び空隙部充てん用組成物調製用キツト | |
| CN115554468A (zh) | 含生物活性玻璃的骨水泥及其制备方法和应用 | |
| RU2236217C1 (ru) | Цемент для замещения костной ткани | |
| KR102209945B1 (ko) | 골조직 생성세포의 이동통로를 제공하는 골 시멘트 제조용 분말상 조성물 |